The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Percutaneous tricuspid valve annuloplasty: additional data and remaining questions

EuroIntervention 2021;17:783-784. DOI: 10.4244/EIJV17I10A134

1. Université de Paris, PARCC, INSERM, Paris, France; 2. European Hospital Georges Pompidou (Cardiology Department), Paris, France; 3. Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany; 4. Munich Heart Alliance, Partner Site German Center for Cardiovascular Disease (DZHK), Munich, Germany
Moderate to severe tricuspid regurgitation (TR) is common and associated with an increased risk of hospitalisation due to heart failure as well as cardiovascular mortality1,2. Tricuspid valve (TV) surgery is often a high-risk procedure with these patients due to late referrals, comorbidities (such as previous cardiac surgery), frailty and/or advanced age3,4. Transcatheter tricuspid valve repair (TTVR) was developed for patients with severe symptomatic TR who were deemed ineligible for cardiac surgery. Although several techniques are available, edge-to-edge repair is currently the most widely used TTVR technique5,6,7.

In this issue of EuroIntervention, Nickenig et al present the 30-day outcomes ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Bioprosthetic valve fracture: haemodynamically effective but safe and clinically necessary?